论文部分内容阅读
目的:探讨尼莫地平联合生脉注射液治疗高血压脑出血的临床疗效。方法:选择发病24h内入院的高血压脑出血患者56例,随机分为治疗组与对照组。2组均给予降颅压、降血压以及营养脑细胞等常规治疗,治疗组同时加用尼莫地平和生脉注射液。比较2组治疗前、后颅内血肿、血肿周围水肿体积及神经功能缺损(CSS)评分的改变,并比较2组的治疗效果。结果:2周时,治疗组血肿+水肿体积较对照组小,CSS评分低于对照组,差异具有统计学意义(P<0.05);4周时,治疗组血肿+水肿体积均较对照组明显缩小,CSS评分明显低于对照组,差异具有高度统计学意义(P<0.01);8周时,治疗组CSS评分明显低于对照组,差异具有高度统计学意义(P<0.01)。治疗组与对照组有效率分别为96.43%、71.43%,差异具有统计学意义(P<0.05)。结论:尼莫地平和生脉注射液的早期联合应用治疗高血压脑出血有利于血肿的吸收和脑水肿的减轻,可改善脑出血患者的预后。
Objective: To investigate the clinical effect of nimodipine and Shengmai injection in treating hypertensive intracerebral hemorrhage. Methods: Fifty-six patients with hypertensive intracerebral hemorrhage admitted within 24 hours after onset were randomly divided into treatment group and control group. 2 groups were given intracranial pressure, blood pressure and nutritional brain cells and other conventional treatment, while the treatment group with nimodipine and Shengmai injection. The changes of edema volume and neurological deficit (CSS) score in the two groups before and after treatment were compared, and the treatment effect was compared between the two groups. Results: At 2 weeks, the volume of hematoma and edema in the treatment group was smaller than that in the control group, and the CSS score was lower than that in the control group (P <0.05). At 4 weeks, the volume of hematoma and edema in the treatment group was significantly higher than that of the control group (P <0.01). At 8 weeks, the CSS score of the treatment group was significantly lower than that of the control group, the difference was highly statistically significant (P <0.01). The effective rates of the treatment group and the control group were 96.43% and 71.43%, respectively, with significant difference (P <0.05). Conclusion: The early combination of nimodipine and Shengmai injection in treating hypertensive intracerebral hemorrhage is beneficial to the absorption of hematoma and the edema of cerebral edema, which can improve the prognosis of patients with intracerebral hemorrhage.